Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 17, 2016

Norgine extends partnership with Apharm to market Ziverel in European countries

Netherlands-based pharma company Norgine has expanded its agreement with Apharm over the distribution of Ziverel, a class-III medical device, in Austria, Belgium, Denmark, Finland, Germany, Ireland, Luxembourg, the Netherlands, Norway, Sweden, Switzerland and the UK.

Netherlands-based pharma company Norgine has expanded its agreement with Apharm over the distribution of Ziverel, a class-III medical device, in Austria, Belgium, Denmark, Finland, Germany, Ireland, Luxembourg, the Netherlands, Norway, Sweden, Switzerland and the UK.

Ziverel is used to maintain the integrity of the oesophageal mucosa to deter the irritation of the oesophagus caused by stomach acid among other causes.

Gastrooesophageal reflux is a commonly occurred disease across the world and disease burden is said to be increasing. It affects up to 20% of the Western population and is associated with a range of risk factors.

Ziverel is a combination of hyaluronic acid and chondroitin sulfate, which shields the oesophageal mucosa by an original mechanism.

"Patients who suffer from gastro-oesophageal reflux symptoms will have access to a new treatment option for a condition that is on the rise."

The high bioadhesive capacity component (poloxamer 407) present in the formulation enhances the stability of contact between the chondroitin sulfate and hyaluronic acid in the surface of the wall of the oesophagus and contributes to the protective effect against the action of hydrochloric acid and pepsin produced by the stomach.

Chondroitin sulfate also performs an action that promotes the repair process of the oesophageal mucosa.

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
“This technique means everything to us”: How CGM devices empower users 
Ensuring quality and supply chain visibility for medical device components

Norgine COO Peter Martin said: "By ensuring Ziverel is widely available in the EU, patients who suffer from gastro-oesophageal reflux symptoms will have access to a new treatment option for a condition that is on the rise and can have a significant impact on health-related quality of life and reduction in personal and work-related productivity."

Last year, Norgine entered into an agreement with Apharm to market Ziverel in Spain, Australia and New Zealand.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU